Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Trius Therapeutics,'s Enterprise Value is €495.19 Mil.
Trius Therapeutics,'s EBIT for the trailing twelve months (TTM) ended in Jun. 2013 was €-52.15 Mil. Therefore, Trius Therapeutics,'s EV-to-EBIT ratio for today is -9.50.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Trius Therapeutics,'s Enterprise Value is €495.19 Mil.
Trius Therapeutics,'s EBITDA for the trailing twelve months (TTM) ended in Jun. 2013 was €-51.63 Mil. Therefore, Trius Therapeutics,'s EV-to-EBITDA ratio for today is -9.59.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Trius Therapeutics,'s Enterprise Value is €495.19 Mil.
Trius Therapeutics,'s Revenue for the trailing twelve months (TTM) ended in Jun. 2013 was €10.88 Mil. Therefore, Trius Therapeutics,'s EV-to-Revenue ratio for today is 45.53.
Trius Therapeutics, Enterprise Value Historical Data
The historical data trend for Trius Therapeutics,'s Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Trius Therapeutics,'s Enterprise Value
For the Diagnostics & Research subindustry, Trius Therapeutics,'s Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Trius Therapeutics,'s Enterprise Value Distribution in the Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Trius Therapeutics,'s Enterprise Value distribution charts can be found below:
* The bar in red indicates where Trius Therapeutics,'s Enterprise Value falls into.
Trius Therapeutics, Enterprise Value Calculation
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Trius Therapeutics,'s Enterprise Value for the fiscal year that ended in Dec. 2012 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Trius Therapeutics, (FRA:TEU) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Trius Therapeutics,'s current Enterprise Value is €495.19 Mil.
Trius Therapeutics,'s EBIT for the trailing twelve months (TTM) ended in Jun. 2013 adds up the quarterly data reported by the company within the most recent 12 months, which was €-52.15 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Trius Therapeutics,'s current Enterprise Value is €495.19 Mil.
Trius Therapeutics,'s EBITDA for the trailing twelve months (TTM) ended in Jun. 2013 adds up the quarterly data reported by the company within the most recent 12 months, which was €-51.63 Mil.
Trius Therapeutics,'s current Enterprise Value is €495.19 Mil.
Trius Therapeutics,'s Revenue for the trailing twelve months (TTM) ended in Jun. 2013 adds up the quarterly data reported by the company within the most recent 12 months, which was €10.88 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Trius Therapeutics, Enterprise Value Related Terms
Thank you for viewing the detailed overview of Trius Therapeutics,'s Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Trius Therapeutics, (FRA:TEU) Business Description
Trius Therapeutics, Inc., was incorporated in California in June 2004. It is a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibiotics for serious infections. The Company is developing tedizolid phosphate, a new, novel antibiotic, for the treatment of serious Gram-positive bacterial infections, including those caused by methicillin-resistant staphylococcus aureus, or MRSA. Tedizolid phosphate is being developed for acute bacterial skin and skin structure infections, or ABSSSI, and pneumonia, and potentially for other indications. ABSSSI is the current classification for complicated skin and skin structure infections. In addition, the company is discovering antibiotics for infections caused by Gram-negative bacteria using its structure based discovery platform. In December 2011, it reported top line data from its first Phase 3 clinical trial, the ESTABLISH 1 (TR701-112) study, of the oral dosage form of tedizolid phosphate for the treatment of ABSSSI. All primary and secondary endpoints for the ESTABLISH 1 study were achieved. In December 2012, the company completed enrollment in its second Phase 3 clinical trial, the ESTABLISH 2 (TR701-113) study, of the intravenous to oral transition therapy for the treatment of ABSSSI. Its current development efforts are focused on developing tedizolid phosphate (formerly known as torezolid phosphate), an intravenous, or IV, and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections and subsequently for other indications, including pneumonia. ABSSSI is a new classification for complicated skin and skin structure infections. Tedizolid phosphate is an IV and orally administered second generation oxazolidinone. Its strategy is to discover and develop a pipeline of antibiotics focused on the treatment of life-threatening infections, consisting of tedizolid phosphate and additional compounds discovered internally using its proprietary discovery platform. The Company employs the services of Albany Molecular Research Incorporated to produce tedizolid phosphate API and Patheon, Inc., or Patheon, to produce the solid oral and sterile IV tedizolid phosphate finished products. It currently employs internal resources and third-party consultants to manage its manufacturing contractors. Its competitors include large pharmaceutical and biotechnology companies, specialty pharmaceutical and generic drug companies, academic institutions, government agencies and research institutions. The Company is subject to a variety of foreign regulations governing clinical trials and commercial sales and distribution of its products to the extent it choose to sell any products outside of the United States.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FRA:TEU has been successfully added to your 